1. Home
  2. HAL vs RPRX Comparison

HAL vs RPRX Comparison

Compare HAL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Halliburton Company

HAL

Halliburton Company

HOLD

Current Price

$28.59

Market Cap

23.2B

Sector

Energy

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$39.70

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAL
RPRX
Founded
1919
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2B
16.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HAL
RPRX
Price
$28.59
$39.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
16
3
Target Price
$31.00
$46.00
AVG Volume (30 Days)
10.1M
4.3M
Earning Date
01-21-2026
11-05-2025
Dividend Yield
2.39%
2.21%
EPS Growth
N/A
N/A
EPS
1.52
1.75
Revenue
$22,137,000,000.00
$2,349,844,000.00
Revenue This Year
N/A
$37.13
Revenue Next Year
N/A
$1.48
P/E Ratio
$18.77
$22.68
Revenue Growth
N/A
3.70
52 Week Low
$18.72
$24.05
52 Week High
$30.86
$41.24

Technical Indicators

Market Signals
Indicator
HAL
RPRX
Relative Strength Index (RSI) 68.44 57.50
Support Level $26.04 $39.24
Resistance Level $25.94 $40.50
Average True Range (ATR) 0.83 0.91
MACD 0.12 -0.08
Stochastic Oscillator 95.17 76.02

Price Performance

Historical Comparison
HAL
RPRX

About HAL Halliburton Company

Halliburton is North America's largest oilfield-services company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. Halliburton's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been honed over a century of operations.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: